This includes TLR1/2 stimulation, which increases myeloma apoptosis at least partially through caspase-3 activation4, and increased cell death and anti-myeloma activity following TLR9 ligation in combination with bortezomib5. Here, TLR9 is linked to plasma cell myeloma.